Given that cognitive decline in Alzheimer’s disease is more closely related to tau accumulation than to amyloid accumulation (Nelson et al., 2012; Ossenkoppele et al., 2016; Bejanin et al., 2017), understanding why certain individuals may have relatively more resistance (avoidance) or resilience (coping) against tau deposition may be crucial for improved risk stratification and therapeutic targeting in Alzheimer’s disease (Arenaza-Urquijo and Vemuri, 2018). The gene discussed is MAPT; the disease is Mental deterioration.